Hypericin and resveratrol anti-tumor impact through E-cadherin, N-cadherin, galectin-3, and BAX/BCL-ratio; possible cancer immunotherapy succor on Y79 retinoblastoma cells

Abstract

One of the detrimental features of retinoblastoma is highly invasiveness of this type of cancer; the ability to metastasize into distal organs even in the early stages. This phenomenon highlights the importance of experiments targeting this characteristic to diminish the disquieting outcomes. In this study we assessed the impact of hypericin, and resveratrol (two main herbal extracts with known anti-cancer properties on the important metastasis/cancer progression pathways in Y79 retinoblastoma cell line). MTT assay performed for 24 and 48 h, and the kind of cell death, investigated by Annexin V/PI flowcytometry. Finally, the expression of important metastatic/apoptotic genes assessed in different samples by the aid of real-time PCR. The 24 and 48 h IC50 for resveratrol, and hypericin was about 10.87 and 7.697, 2.267, and 1.732 μg/mL, respectively. Flowcytometry results revealed that the kind cell death after treatment of Y79 cell with both compounds was mostly apoptosis. Both compounds induced up-regulation of E-cad, and down-regulation of N-cad, and Gal-3; furthermore, BAX/BCL-2 ratio increased significantly in cells treated with hypericin. Hypericin seems to exert more cytotoxicity effect on Y79 cells compared with resveratrol. As both compounds enhanced the expression of the E-cadherin, along with the decreasing the galectin-3, they can be proposed as beneficial accompanying reagents in cancer immunotherapy.

Keywords

cadherin / galectin-3 / metastasis / retinoblastoma

References

[1] Tondro F, Shahbazi S, Shahriari F, et al. Inhibition by hypericin of tongue squamous carcinoma cell proliferation and treatment of resistance in dental pulp stem cells. Rev Brasil Farmacog. 2024; 34(4): 767-775.

[2] Ghiasvand S, Javidi MA, Mohammadian A, Mousavi SA, Shahriari F, Alavian F. Transcriptome analysis evinces anti-neoplastic mechanisms of hypericin: A study on U87 glioblastoma cell line. Life Sci. 2021; 266: 118874.

[3] Ko JH, Sethi G, Um JY, et al. The role of resveratrol in cancer therapy. Int J Mol Sci. 2017; 18(12): 2589.

[4] Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020; 5(1): 28.

[5] Chen X, Wang J, Cao Z, et al. Invasiveness and metastasis of retinoblastoma in an orthotopic zebrafish tumor model. Sci Rep. 2015; 5: 10351.

[6] Kim HA, Yoon YH, Kim JG, Lee JY. Clinical features and long-term prognosis of retinoblastoma according to age at diagnosis. Korean Jo of Ophthalmol: KJO. 2020; 34(3): 242-250.

[7] Li YD, Lv Z, Xie HY, Zheng SS. Retinoblastoma binding protein 4 up-regulation is correlated with hepatic metastasis and poor prognosis in colon cancer patients. Hepatobiliary Pancreatic Dis Int: HBPD INT. 2019; 18(5): 446-451.

[8] Yu F, Jiang Z, Song A. Association of rs11801299 and rs1380576 polymorphisms at MDM4 with risk, clinicopathological features and prognosis in patients with retinoblastoma. Cancer Epidemiol. 2019; 58: 153-159.

[9] Horowitz JM, Yandell DW, Park SH, et al. Point mutational inactivation of the retinoblastoma antioncogene. Science. 1989; 243(4893): 937-940.

[10] Alefeld E, Haase A, Van Meenen D, et al. In vitro model of retinoblastoma derived tumor and stromal cells for tumor microenvironment (TME) studies. Cell Death Dis. 2024; 15(12): 905.

[11] Kozlova I, Sytnyk V. Cell adhesion molecules as modulators of the epidermal growth factor receptor. Cells. 2024; 13(22): 1919.

[12] Machaty Z. The signal that stimulates mammalian embryo development. Front Cell Dev Biol. 2024; 12: 1474009.

[13] da Rosa Franchi Santos LF, Costa NT, Maes M, Simao ANC, Dichi I. Influence of treatments on cell adhesion molecules in patients with systemic lupus erythematosus and rheumatoid arthritis: a review. Inflammopharmacology. 2020; 28(2): 363-384.

[14] Lewczuk L, Pryczynicz A, Guzinska-Ustymowicz K. Cell adhesion molecules in endometrial cancer - A systematic review. Adv Med Sci. 2019; 64(2): 423-429.

[15] Uyemura K. Review of neural cell adhesion molecules. Tanpakushitsu Kakusan Koso Protein, Nucleic Acid, Enzyme. 1997; 42(3 Suppl): 519-524.

[16] Mirandola L, Nguyen DD, Rahman RL, et al. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 2014; 33(5): 417-427.

[17] Peplau E, De Rose F, Reder S, et al. Development of a chimeric antigen-binding fragment directed against human Galectin-3 and validation as an Immuno-positron emission tomography tracer for the sensitive in vivo imaging of thyroid cancer. Thyroid. 2020; 30: 1314-1326.

[18] Zhang H, Luo M, Liang X, et al. Correction: Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS One. 2020; 15(4): e0232166.

[19] Almatroodi SA, M AA, A SMA, et al. Potential therapeutic targets of resveratrol, a plant polyphenol, and its role in the therapy of various types of cancer. Molecules. 2022; 27(9): 1-38.

[20] Peng L, Jiang D. Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition. PLoS One. 2018; 13(10): e0205918.

[21] Kursvietiene L, Kopustinskiene DM, Staneviciene I, et al. Anti-cancer properties of resveratrol: A focus on its impact on mitochondrial functions. Antioxidants (Basel). 2023; 12(12): 2056.

[22] Gamasaee NA, Radmansouri M, Ghiasvand S, et al. Hypericin induces apoptosis in MDA-MB-175-VII cells in lower dose compared to MDA-MB-231. Arch Iran Med. 2018; 21(9): 387-392.

[23] Hosseini MM, Karimi A, Behroozaghdam M, et al. Cytotoxic and apoptogenic effects of cyanidin-3-glucoside on the glioblastoma cell line. World Neurosurg. 2017; 108: 94-100.

[24] Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012; 379(9824): 1436-1446.

[25] Zaferani Arani H, Abbasy Z, Abbasy SMR, et al. Hypericin and naringenin exert no significant synergistic apoptotic effect on Y79 retinoblastoma cell line. Galen Med J. 2024; 13: 1-8.

[26] Arani HZ, Olya M, Mirahmadi AS, et al. Hypericin induces apoptosis in K562 cells via downregulation of Myc and Mdm2. J Cancer Res Ther. 2021; 17(1): 242-247.

[27] Naderi M, Rahmani Cherati M, Mohammadian A, et al. Hypericin induces apoptosis in AGS cell line with No significant effect on Normal cells. Iran J Pharm Res. 2020; 19(3): 349-357.

[28] Olya M, Zaferani Arani H, Shekarriz A, et al. Hypericin exerts detrimental effect on Huh-7 As a delegacy of hepatocellular carcinoma: A P53 dependent pathway. Galen Med J. 2020; 9: e1896.

[29] Piryaei M, Mehrparvar B, Mohammadian A, Shahriari F, Javidi MA. Anti-cancer impact of hypericin in B-CPAP cells: extrinsic caspase dependent apoptosis induction and metastasis obstruction. Eur J Pharmacol. 2021; 910: 174454.

[30] Rani N, Bharti S, Krishnamurthy B, et al. Pharmacological properties and therapeutic potential of naringenin: A citrus flavonoid of pharmaceutical promise. Curr Pharm des. 2016; 22(28): 4341-4359.

[31] Li L, Xu B, Li CR, et al. Anti-proliferation and apoptosis-inducing effects of sodium aescinate on retinoblastoma Y79 cells. Int J Ophthalmol. 2020; 13(10): 1546-1553.

[32] Ratajczak K, Glatzel-Plucinska N, Ratajczak-Wielgomas K, Nowinska K, Borska S. Effect of resveratrol treatment on human pancreatic cancer cells through alterations of Bcl-2 family members. Molecules. 2021; 26(21): 6560.

[33] Kolahdouz-Mohammadi R, Delbandi AA, Khodaverdi S, Arefi S, Arablou T, Shidfar F. The effects of resveratrol treatment on Bcl-2 and Bax gene expression in endometriotic compared with non-endometriotic stromal cells. Iran J Public Health. 2020; 49(8): 1546-1554.

[34] Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002; 8(3): 893-903.

[35] Lialios P, Alimperti S. Role of E-cadherin in epithelial barrier dysfunction: implications for bacterial infection, inflammation, and disease pathogenesis. Front Cell Infect Microbiol. 2025; 15: 1506636.

[36] Iwata T, Nozu F, Imawari M. Ethanol impairs the assembly and disassembly of actin cytoskeleton and cell adhesion via the RhoA signaling pathway, catenin p120 and E-cadherin in CCK-stimulated pancreatic acini. Biochem Biophys Res Commun. 2011; 405(4): 558-563.

[37] Dai L, Zhao J, Yin J, Fu W, Chen G. Cell adhesion molecule 2 (CADM2) promotes brain metastasis by inducing epithelial-mesenchymal transition (EMT) in human non-small cell lung cancer. Ann Transl Med. 2020; 8(7): 465.

[38] Yang L, Yu Y, Xiong Z, Chen H, Tan B, Hu H. Downregulation of SEMA4C inhibit epithelial-mesenchymal transition (EMT) and the invasion and metastasis of cervical cancer cells via inhibiting transforming growth factor-beta 1 (TGF-beta1)-induced Hela cells p38 mitogen-activated protein kinase (MAPK) activation. Med Sci Monit. 2020; 26: e918123.

[39] Li X, Lin S, Mo Z, et al. CircRNA_100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228/p53/epithelial-mesenchymal transition (EMT) axis. J Cancer. 2020; 11(3): 599-609.

[40] Zasadkevich YM, Sazonov SV. The role of E-cadherin cell adhesion molecule in human ontogenesis in norm and pathology. Morfologiia. 2014; 146(5): 78-82.

[41] Georgolios A, Eleftheriadou A, Batistatou A, Charalabopoulos K. Role of the recently identified dysadherin in E-cadherin adhesion molecule downregulation in head and neck cancer. Med Oncol. 2012; 29(3): 1463-1467.

[42] San SH, Ngai SC. E-cadherin re-expression: its potential in combating TRAIL resistance and reversing epithelial-to-mesenchymal transition. Gene. 2024; 909(148293): 1-16.

[43] Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011; 108(29): 11930-11935.

[44] Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res. 2009; 19(1): 89-102.

[45] Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004; 23(8): 1739-1748.

[46] Kim NG, Gumbiner BM. Adhesion to fibronectin regulates hippo signaling via the FAK-Src-PI3K pathway. J Cell Biol. 2015; 210(3): 503-515.

[47] Casal JI, Bartolome RA. Beyond N-cadherin, relevance of cadherins 5, 6 and 17 in cancer progression and metastasis. Int J Mol Sci. 2019; 20(13): 1-20.

[48] Bhandari A, Zheng C, Sindan N, et al. COPB2 is up-regulated in breast cancer and plays a vital role in the metastasis via N-cadherin and vimentin. J Cell Mol Med. 2019; 23(8): 5235-5245.

[49] Guo B, Zhang J, Li Q, et al. Hypermethylation of miR-338-3p and impact of its suppression on cell metastasis through N-cadherin accumulation at the cell -cell junction and degradation of MMP in gastric cancer. Cell Physiol Biochem. 2018; 50(2): 411-425.

[50] Mrozik KM, Blaschuk OW, Cheong CM, Zannettino ACW, Vandyke K. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer. 2018; 18(1): 939.

[51] Jun KH, Lee JE, Kim SH, et al. Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncol Rep. 2015; 34(4): 2047-2053.

[52] Tanaka H, Kono E, Tran CP, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010; 16(12): 1414-1420.

[53] Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer. 2010; 17(2): 469-479.

[54] Li S, Jiao J, Lu Z, Zhang M. An essential role for N-cadherin and beta-catenin for progression in tongue squamous cell carcinoma and their effect on invasion and metastasis of Tca8113 tongue cancer cells. Oncol Rep. 2009; 21(5): 1223-1233.

[55] Gerber TS, Ridder DA, Goeppert B, et al. N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas. Int J Cancer. 2024; 154(10): 1857-1868.

[56] Xiao Y, Zhou L, Andl T, Zhang Y. YAP1 controls the N-cadherin-mediated tumor-stroma interaction in melanoma progression. Oncogene. 2024; 43: 884-898.

[57] Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res. 2009; 81(1): 178-186.

[58] Lin CI, Whang EE, Donner DB, et al. Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res: MCR. 2009; 7(10): 1655-1662.

[59] Lee SH, Khwaja Rehman F, Tyler KC, et al. A chimeric signal peptide-Galectin-3 conjugate induces glycosylation-dependent cancer cell-specific apoptosis. Clin Cancer Res. 2020; 26(11): 2711-2724.

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.